Medistep Healthcare Limited (NSE:MEDISTEP)
India · Delayed Price · Currency is INR 22.50
0.00 (0.00%)
At close: Sep 11, 2026
Medistep Healthcare Income Statement
Financials in millions INR. Fiscal year is April - March.
Millions INR. Fiscal year is Apr - Mar.
Fiscal Year | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
Operating Revenue | 708.31 | 496.55 | 390.72 | 276.47 | 76.24 |
Other Revenue | - | 0 | - | - | - |
| 708.31 | 496.55 | 390.72 | 276.47 | 76.24 | |
Revenue Growth | 42.65% | 27.09% | 41.33% | 262.61% | - |
Cost of Revenue | 618.27 | 435.59 | 341.93 | 261.26 | 70.53 |
Gross Profit | 90.05 | 60.96 | 48.79 | 15.21 | 5.71 |
Selling, General & Admin | 2.96 | 3.06 | 1.99 | 1.42 | 1.4 |
Other Operating Expenses | 4.39 | 1.89 | 1.28 | 0.4 | 0.73 |
Operating Expenses | 7.62 | 5.28 | 3.49 | 2.48 | 2.75 |
Operating Income | 82.43 | 55.68 | 45.3 | 12.74 | 2.96 |
Interest Expense | -1.54 | -0.3 | -0.84 | -1.33 | -0.43 |
Other Non Operating Income (Expenses) | -0.95 | - | 0 | 0 | - |
EBT Excluding Unusual Items | 79.94 | 55.38 | 44.47 | 11.41 | 2.54 |
Gain (Loss) on Sale of Investments | 0.01 | - | - | - | - |
Gain (Loss) on Sale of Assets | - | - | - | 0.9 | - |
Pretax Income | 79.95 | 55.38 | 44.47 | 12.31 | 2.54 |
Income Tax Expense | 20.12 | 13.94 | 11.19 | 3.1 | 0.64 |
Net Income | 59.83 | 41.44 | 33.28 | 9.21 | 1.9 |
Preferred Dividends & Other Adjustments | - | - | 4.14 | - | - |
Net Income to Common | 59.83 | 41.44 | 29.14 | 9.21 | 1.9 |
Net Income Growth | 44.38% | 42.23% | 216.34% | 385.50% | - |
Shares Outstanding (Basic) | 13 | 10 | 1 | - | - |
Shares Outstanding (Diluted) | 13 | 10 | 1 | - | - |
Shares Change | 23.66% | 608.37% | - | - | - |
EPS (Basic) | 4.68 | 4.01 | 19.96 | - | - |
EPS (Diluted) | 4.68 | 4.01 | 19.96 | - | - |
EPS Growth | 16.75% | -79.92% | - | - | - |
Additional Metrics
Fiscal Year | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
Free Cash Flow | -194.86 | 0.21 | -71.15 | 4.42 | - |
Free Cash Flow Per Share | -15.24 | 0.02 | -48.76 | - | - |
Gross Margin | 12.71% | 12.28% | 12.49% | 5.50% | 7.49% |
Operating Margin | 11.64% | 11.21% | 11.59% | 4.61% | 3.88% |
Profit Margin | 8.45% | 8.35% | 7.46% | 3.33% | 2.49% |
Free Cash Flow Margin | -27.51% | 0.04% | -18.21% | 1.60% | - |
EBITDA | 82.7 | 56.01 | 45.52 | 13.39 | 3.58 |
EBITDA Margin | 11.68% | 11.28% | 11.65% | 4.84% | 4.69% |
D&A For EBITDA | 0.27 | 0.33 | 0.22 | 0.65 | 0.62 |
EBIT | 82.43 | 55.68 | 45.3 | 12.74 | 2.96 |
EBIT Margin | 11.64% | 11.21% | 11.59% | 4.61% | 3.88% |
Effective Tax Rate | 25.17% | 25.17% | 25.17% | 25.16% | 25.17% |
Revenue as Reported | 708.54 | 496.59 | 390.82 | 277.37 | 76.24 |
Advertising Expenses | - | - | 0.01 | 0.04 | - |